Daré Bioscience Reports Third Quarter 2026 Financial Results and Highlights Commercial Execution and Pipeline Advancement
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Daré Bioscience (NASDAQ: DARE) reported a narrower third-quarter 2026 net loss as revenue increased and research and development expenses declined. Net loss was approximately $3.2 million, versus $3.6 million a year earlier; revenue rose to approximately $48,000 from $2,300. Cash and cash equivalents were approximately $11.5 million, with working capital of approximately $3.2 million at September 30.
The company expects DARE to PLAY prescription dispensing in November 2026 in 28 states, following prescriptions written across 48 states and Washington, D.C. Flora Sync LF5 began generating sales in July. Daré expects 2026 product revenue to be immaterial and targets DARE to RECLAIM dispensing in 2027. Ovaprene Phase 3 and DARE-HPV Phase 2 topline results are anticipated in 2027. Daré has secured more than $75 million in non-dilutive grant awards and is exploring collaborations for its programmable drug-delivery platform.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major pointGrant awards exceed $75 million, providing non-dilutive funding for pipeline development. 5.8× market cap
- Moderate point. Forward-looking: it has not happened yet and may not happen.DARE to PLAY dispensing is expected in November 2026 in 28 states through the Section 503B compounding pathway.
- Moderate point. Forward-looking: it has not happened yet and may not happen.DARE to RECLAIM dispensing is targeted for 2027 through Section 503B, alongside planned conventional drug development.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Ovaprene topline data are anticipated in 2027 from the ongoing pivotal Phase 3 study.
- Moderate pointDARE-PTB2 development is supported by an approximately $0.9 million NICHD grant announced in August 2026. 7% of market cap
- Moderate pointDARE-LARC1 funding reached approximately $43.3 million following October's $1.5 million payment under an up-to-$49.0-million agreement. 12% of market cap
9 minor points
- Minor pointThird-quarter revenue increased to approximately $48,000 from approximately $2,300, primarily from research and development services.
- Minor pointQuarterly net loss narrowed to approximately $3.2 million from approximately $3.6 million a year earlier.
- Minor pointQuarterly research and development expenses declined to approximately $0.3 million from approximately $1.2 million.
- Minor pointDARE to PLAY prescriptions span 48 states and Washington, D.C.; office-based prescribers total 182, excluding telehealth.
- Minor pointFlora Sync LF5, Daré's first directly commercialized product, began sales in July and received its first provider office reorder.
- Minor pointOvaprene Phase 3 previously reported positive interim results; independent safety monitors recommended continuation without modification.
- Minor point. Forward-looking: it has not happened yet and may not happen.DARE-HPV Phase 2 is advancing, with approximately 100 women expected and topline results anticipated in 2027.
- Minor pointOvaprene-related grant funding included an approximately $0.9 million November 2026 payment, the next-to-last anticipated tranche.
- Minor point. Forward-looking: it has not happened yet and may not happen.DARE-IDDS collaborations are being explored in obesity, diabetes, hormone therapies and neurologic disease, including potential GLP-1 applications.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.2026 product revenue is not expected to be material.
- Minor pointQuarterly cost of revenues was approximately $0.2 million, versus no comparable activity a year earlier.
- Minor pointQuarterly selling, general and administrative expenses increased to approximately $2.6 million from approximately $2.5 million.
- Minor point. Forward-looking: it has not happened yet and may not happen.DARE to PLAY dispensing licenses remain to be obtained for states beyond the initial 28.
News Explained
About 43.3 million dollars of up to 49 million dollars in potential DARE-LARC1 grant funding has been received.
Daré reports receiving an October
Flora Sync LF5 has generated orders from 27 states and its first provider-office reorder, which the company describes as an early indication of repeat demand.
Key Figures
- Cash and cash equivalents
- approximately $11.5 million
- As of September 30, 2026
- Working capital
- approximately $3.2 million
- As of September 30, 2026
- Revenue
- approximately $48,000 vs. approximately $2,300
- Three months ended September 30, 2026 vs. the same period in 2025
- Net loss
- approximately $3.2 million vs. approximately $3.6 million
- Third quarter 2026 vs. third quarter 2025
- Loss per common share
- $(0.18) vs. $(0.28)
- Basic and diluted; three months ended September 30, 2026 vs. 2025
- Selling, general and administrative expenses
- approximately $2.6 million vs. approximately $2.5 million
- Third quarter 2026 vs. third quarter 2025
- Research and development expenses
- approximately $0.3 million vs. approximately $1.2 million
- Third quarter 2026 vs. third quarter 2025
- DARE-LARC1 grant funding received
- approximately $43.3 million of up to $49.0 million
- Cumulative funding under the grant agreement, including the October 2026 payment
Previous Earnings Reports
-
Q2 revenue rose and net loss narrowed year over year; cash was $12.6 million.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
section 503b regulatory
505(b)(2) regulatory
glp-1 medicines medical
contra-r&d expenses financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
DARE to PLAY™ Sildenafil Cream prescription dispensing activities underway this month, with prescriptions written across 48 states and Washington, D.C.
Commercial launch of Flora Sync LF5™ showing encouraging early indicators, including orders from 27 states, provider office reorder and positive consumer feedback
Company surpassed
Company to host conference call and webcast today, November 16, 2026, at 4:30 p.m. Eastern Time – Access the webcast here
SAN DIEGO, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today reported financial results for the quarter ended September 30, 2026 and provided a corporate update highlighting commercial execution and continued progress with its development pipeline.
“This is an exciting day for clinicians and women waiting for DARE to PLAY Sildenafil Cream, as the first shipment is on route from the outsourcing facility to Medvantx, the central pharmacy that handles order processing and dispensing. DARE to PLAY provider engagement built demand ahead of dispensing, with prescriptions written across 48 states and Washington, D.C. Our outsourcing facility partner has been working to manufacture supply at a scale to meet anticipated demand, and, with product now on route to Medvantx, we expect prescription dispensing to commence later this month,” said Sabrina Martucci Johnson, Founder, President and Chief Executive Officer of Daré Bioscience.
“For Flora Sync LF5 we built our initial commercial approach around the relationships women have with their healthcare providers, given the clinical data that distinguish Flora Sync LF5 in the category, and the early response to Flora Sync LF5 is encouraging. Recommendations and sampling are helping women discover the product, while our provider office reorder gives us an early indication of repeat demand,” continued Ms. Johnson. “Our priority now is to build on that response and turn initial purchases into sustained growth. We look forward to launching Flora Sync LF5 on Amazon in early 2027, and are pleased to be expanding the DARE to RESTORE™ brand family to include Flora Renew™ and Flora Reset™, a vulvar mask and cleanser, also anticipated in early 2027.”
BUILDING TOWARD A MULTI-PRODUCT COMMERCIAL PORTFOLIO
Daré Bioscience is building a commercial platform designed to make it easier for women to discover, access and purchase products developed specifically for their health needs. The Company’s approach is to bring together evidence-based products, healthcare provider engagement and sampling, targeted digital marketing, telehealth services and the DARE Health Hub to support adoption and repeat purchases across a growing commercial portfolio.
Key Commercial Highlights:
- Flora Sync LF5™: Launched in June 2026, with first sales in July, Flora Sync LF5 is Daré Bioscience’s first directly commercialized product and initial consumer health offering. Available through the DARE Health Hub and directly to healthcare providers for in-office dispensing, the product has generated orders from 27 states and its first provider office reorder. Early consumer feedback includes a 4.9-star review rating after the initial approximately 25 reviews, with customers reporting purchases following a provider recommendation or sample. The Company continues clinician education, sampling and provider outreach to build recommendations, repeat office purchases and consumer demand.
- DARE to PLAY™ Sildenafil Cream*: Daré Bioscience is preparing for prescription dispensing of its proprietary topical sildenafil cream through the Section 503B compounding pathway, with dispensing expected this month in 28 states. The Company has worked with its 503B-registered outsourcing facility partner to prepare to supply at a scale to support anticipated demand, as well as to continue efforts to obtain licenses to dispense DARE to PLAY Sildenafil Cream in the remaining states. Provider engagement has generated prescriptions from 182 office-based prescribers, excluding telehealth. Across office-based providers and telehealth, prescriptions have been written in 48 states and Washington, D.C.
- DARE to RECLAIM™*: Daré Bioscience is preparing for commercial availability of its monthly estradiol and progesterone intravaginal ring through the Section 503B compounding pathway, with prescription dispensing targeted to begin in 2027. In parallel, the Company plans to continue conventional drug product development necessary to pursue a regulatory strategy using the FDA’s 505(b)(2) pathway.
- DARE Health Hub: The Company's digital commercial platform continues to support product discovery, education, access and fulfillment, providing infrastructure intended to support current and future product offerings.
ADVANCING A DIFFERENTIATED WOMEN'S HEALTH PIPELINE
Daré Bioscience continues to progress a diversified pipeline to address significant unmet needs across women’s health, supported in part by non-dilutive grant funding.
“Non-dilutive funding is central to how we develop our pipeline. We have secured more than
- Ovaprene® – Investigational Hormone-Free Monthly Intravaginal Contraceptive: Daré Bioscience previously reported positive interim results from its ongoing pivotal Phase 3 study of Ovaprene (ClinicalTrials.gov ID: NCT06127199), and the independent Data Safety Monitoring Board’s recommendation that the study continue without modification. The Company continues to anticipate reporting topline data from the study in 2027. The program remains a key component of Daré Bioscience's clinical pipeline and is supported by grant funding from the Gates Foundation.
- DARE-HPV – Investigational Therapeutic for Persistent High-Risk HPV Infection: Daré Bioscience is advancing its Phase 2 clinical study of DARE-HPV, an investigational fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert, to evaluate the safety and antiviral activity of DARE-HPV in women with persistent high-risk human papillomavirus (HPV) infection (ClinicalTrials.gov ID: NCT07601074). The study is expected to enroll approximately 100 women, with topline results anticipated in 2027. The program is supported by funding from the Advanced Research Projects Agency for Health (ARPA-H) and the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health. There are currently no FDA-approved pharmacologic treatments for HPV infection.
- DARE-PTB2 – Investigational Program for the Prevention of Preterm Birth: Daré Bioscience continues to advance DARE-PTB2, an early-stage program focused on a novel therapeutic approach intended to address biological mechanisms associated with preterm birth, supported by an approximately
$0.9 million grant award from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) of the National Institutes of Health announced in August 2026. - DARE-LARC1 – Investigational Long-Acting Reversible Contraceptive: Daré Bioscience continues to advance preclinical development of DARE-LARC1, a grant-supported contraceptive program built on the Company's programmable drug delivery technology. The underlying DARE-IDDS platform is designed to control the amount of drug released and the timing of release, offering potential flexibility in how medicines are delivered.
- DARE-IDDS – Investigational Programmable Drug Delivery Platform: DARE-IDDS is the underlying technology behind DARE-LARC1 and is designed to control how much drug is released and when. Daré Bioscience believes this tunability may have broader applications across chronic conditions and is exploring potential strategic collaboration opportunities in areas including obesity, diabetes, hormone therapies and neurologic disease, including potential applications with GLP-1 medicines.
NON-DILUTIVE GRANT FUNDING
Daré Bioscience has secured more than
Recent Grant Awards:
- Ovaprene and Contraceptive Product Candidate: In November 2026, Daré Bioscience received a payment of approximately
$0.9 million under its November 2024 grant agreement with the Gates Foundation supporting the ongoing Phase 3 clinical trial of Ovaprene and the identification and development of a novel non-hormonal intravaginal contraceptive candidate. This payment represents the next-to-last anticipated tranche under the up to approximately$10.7 million grant award. Daré Bioscience received approximately$5.4 million in funding under the agreement in 2024 and approximately$3.6 million in 2025. - DARE-LARC1: In October 2026, Daré Bioscience received a
$1.5 million payment under its June 2021 grant agreement supporting development of DARE-LARC1. Including this payment, the Company has received approximately$43.3 million of the up to$49.0 million in potential funding under the agreement.
FINANCIAL RESULTS FOR THIRD QUARTER 2026 AND HIGHLIGHTS
Cash Position
As of September 30, 2026, Daré Bioscience had approximately
Revenue
Total revenue for the three months ended September 30, 2026 was approximately
Cost of Revenues
Cost of revenues for the three months ended September 30, 2026 was approximately
Operating Expenses
Selling, general and administrative expenses were approximately
Research and development (R&D) expenses were approximately
Daré Bioscience recognizes amounts received under grant and governmental funding awards as “contra-R&D expenses,” meaning grant funding reduces R&D expenses in the statements of operations as the related costs are incurred over the grant period. The Company believes this is important to understand when evaluating the scale of the Company’s R&D investment and capital efficiency. Total contra-R&D expenses for the three months ended September 30, 2026 and 2025 were approximately
Net Loss
Net loss for the three months ended September 30, 2026 was approximately
Revenue Outlook
Daré Bioscience began recording revenue from sales of Flora Sync LF5 in July 2026 and expects to begin recording revenue from sales of DARE to PLAY Sildenafil Cream in the fourth quarter of 2026. The Company does not expect the amount of such product revenue to be material during 2026. Revenue from DARE to RECLAIM estradiol and progesterone intravaginal ring is targeted to begin in 2027. The Company is building toward a multi-product revenue profile that diversifies and grows across 2026 and 2027.
Daré Bioscience encourages investors to review the detailed discussion of its financial statements, financial condition, liquidity, capital resources and risk factors in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, filed today with the U.S. Securities and Exchange Commission (SEC).
Conference Call
Daré Bioscience will host a conference call and live webcast today, November 16, 2026, at 4:30 p.m. Eastern Time to review its financial results for the quarter ended September 30, 2026, and to provide a company update.
To access the conference call via phone, dial (646) 307-1963 or (800) 715-9871 (toll-free). The conference ID number for the call is 5942376. The live webcast can be accessed under “Presentations, Events & Webcasts" in the Investors section of the company's website at ir.darebioscience.com. Please log in approximately 5-10 minutes prior to the call to register and to download and install any necessary software. The webcast will be archived in the same section of the company's website and available for replay for 90 days.
ABOUT DARÉ BIOSCIENCE, INC.
Daré Bioscience (NASDAQ: DARE) is a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions. Every innovation Daré Bioscience advances is based in advanced science and backed by rigorous, peer-reviewed research. From contraception to menopause, sexual health to fertility, vaginal health to infectious disease, Daré Bioscience is working to close critical gaps in care using science that serves her needs. For decades, women have been told to “wait it out” or “live with it,” while innovations that could improve their quality of life languish in the regulatory or funding pipeline. With growing awareness around menopause, sexual health, and vaginal health, the conversation is shifting. However, access to proven solutions is lagging. Daré Bioscience is working to change that. Learn more at darebioscience.com.
FORWARD-LOOKING STATEMENTS
Daré Bioscience cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “plan,” “potential,” “prepare,” “progress,” “seek,” “should,” “would,” “build,” “grow,” “pursue,” “target,” or the negative version of these words and similar expressions.
In this press release, forward-looking statements include, but are not limited to, statements relating to: Daré Bioscience’s commercial strategy and plans, including anticipated products and their timing to market; the significance of the number, source and geographic scope of prescriptions for DARE to PLAY received during the pre-fulfillment period; the significance of the number of states from which Flora Sync LF5 has been ordered, the first provider office reorder and early consumer reviews of the product; the capabilities of the Company’s commercial infrastructure and potential expansion of the platforms through which products may be sold; the ability of the outsourcing facility to provide sufficient quantities of DARE to PLAY to meet anticipated demand and to obtain required state licensing to dispense DARE to PLAY in additional states; the timing and materiality of future product revenue; the potential demand and market opportunity for the Company’s products and their ability to gain market acceptance; potential commercial portfolio expansion; development and regulatory pathway plans and expectations regarding the Company’s investigational products, including regulatory strategy, clinical development strategies, clinical study timelines, and timing of topline results announcements; the potential for product candidates in clinical and preclinical development to demonstrate safety and effectiveness for the respective indications for which they are being developed; the potential for DARE-HPV to advance in clinical development and in the future become the first pharmacologic treatment approved for the treatment of HPV infection; the potential application of DARE-IDDS for therapeutic products in a broad range of conditions and diseases; expectations regarding non-dilutive funding, including the anticipated impact of funding received to date and the potential to obtain additional non-dilutive funding awards; expectations regarding existing and potential future strategic collaborations; and the potential for products that the Company brings to market to address significant unmet needs in women’s health.
Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Daré Bioscience’s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation, risks and uncertainties related to: the Company’s ability to obtain additional capital when and as needed to execute its business strategy and continue as a going concern; potential suspension and delisting of the Company’s common stock from the Nasdaq Capital Market; the Company’s dependence on grants and other financial awards from governmental entities and a private foundation and the risk that anticipated funding may be reduced, delayed, or terminated, or may be insufficient to advance a product candidate into or through a particular development milestone as anticipated; the Company’s reliance on Section 503B-registered outsourcing facilities and other third parties to bring DARE to PLAY Sildenafil Cream and other solutions to market as compounded drugs or as consumer health products and facilitate access to such products and the risk that those third parties do not perform as expected; difficulties in establishing and sustaining relationships with third-party collaborators; the risk that the U.S. Food and Drug Administration (FDA) could stop permitting Section 503B-registered outsourcing facilities to compound the drug substances in the proprietary formulations the Company intends to bring or brings to market or changes the conditions under which those drug substances may be used in compounding or the compounded products may be distributed; the ability of outsourcing facilities with which the Company collaborates to maintain their registration with the FDA under Section 503B of the Federal Food, Drug, and Cosmetic Act; the timing of establishing, and ability to maintain, state-required licensure or registration to enable fulfillment of prescriptions for DARE to PLAY Sildenafil Cream and other solutions brought to market via the Section 503B pathway; the Company’s inexperience, as a company, in and limited infrastructure for commercializing products; the degree of market demand and acceptance for the products the Company brings to market; competitive product launches; greater than expected costs to bring compounded drug products to market and marketing costs; shifts in consumer spending or behavior; failure or delay in commencing, conducting or completing clinical trials on anticipated timelines, or at all, and the inherent uncertainty of outcomes of clinical trials; the risk that positive findings in technological proof-of-concept studies, other nonclinical studies and/or early clinical studies of a product candidate or technology may not be predictive of success in subsequent clinical and/or nonclinical studies of that candidate or technology; the risk that interim results from a particular clinical study do not predict the final results for that study; decisions not to make clinical study design modifications recommended by the FDA; the risk that even if a pivotal clinical study achieves its primary efficacy endpoint, the FDA may determine the data package is not sufficient to support a favorable benefit-risk determination in a future marketing application; the Company’s dependence on third parties to conduct clinical and nonclinical studies and manufacture and supply clinical trial material and commercial product; the potential that a product candidate in clinical development may never advance into or through a pivotal clinical study or obtain FDA or foreign regulatory approval; the risk that the FDA, other regulatory authorities, members of the scientific or medical communities or investors may not accept or agree with Daré Bioscience's interpretation of or conclusions regarding data from clinical studies of its product candidates; the risk that development of a product candidate requires more clinical or nonclinical studies than Daré Bioscience anticipates; the risk that the FDA’s 505(b)(2) pathway** may not be available for a product candidate as Daré anticipates; failure of the Company’s product candidates, if approved, to gain market acceptance or obtain adequate coverage, pricing and reimbursement from third-party payors; the loss of, or inability to attract, key personnel; the Company’s ability to retain its licensed rights to develop and commercialize a product or product candidate; the Company’s ability to satisfy the monetary obligations and other requirements in connection with its exclusive, in-license agreements covering the critical patents and related intellectual property related to its product and product candidates; the Company’s ability to adequately protect or enforce its, or its licensor’s, intellectual property rights; disputes or other developments concerning the Company’s intellectual property rights; the lack of patent protection for the active ingredients in certain of the Company’s product candidates which could expose its products to competition from other formulations using the same active ingredients; product liability claims; governmental investigations or actions relating to the Company’s products or product candidates or the business activities of the Company’s, its commercial collaborators or other third parties on which the Company relies; changes in healthcare, pharmaceutical, consumer protection or privacy laws and regulatory policies; increased scrutiny from regulators; global trends toward health care cost containment; the effects of macroeconomic conditions, geopolitical events, and major changes and disruptions in U.S. government policies and operations on the Company’s ability to raise additional capital or on the Company’s operations, financial results and condition, and ability to achieve current plans and objectives; and cybersecurity incidents or similar events that compromise the Company’s technology systems and/or significantly disrupt the Company’s business or those of third parties on which it relies.
Daré Bioscience’s forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of the Company’s risks and uncertainties, you are encouraged to review its documents filed with the U.S. Securities and Exchange Commission (SEC), including the Company’s recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Daré Bioscience undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
*The terms DARE to PLAY and DARE to RECLAIM describe 503B compounded drug products. Compounded drug products are not approved by the FDA. The FDA does not evaluate compounded drug products for safety, effectiveness, or quality. References to Section 503B, 503B, 503B compounding, 503B compounded product, and similar terms refer to Section 503B of the Federal Food, Drug, and Cosmetic Act (FDCA) and the production and supply of compounded drugs by Section 503B-registered outsourcing facilities without patient-specific prescriptions in accordance with Section 503B. Section 503B-registered outsourcing facilities are subject to FDA inspection and required to compound drug products under current Good Manufacturing Practice (cGMP) regulations to ensure quality, strength and consistency.
**The term FDA 505(b)(2) regulatory pathway refers to Section 505(b)(2) of the FDCA, which enables an applicant to rely, in part, on the FDA’s prior findings of safety and efficacy data for an existing product, or published literature, in support of the applicant’s new drug application (NDA), providing an alternate path to FDA approval for new or improved formulations or new uses of previously approved drugs.
Contact:
Daré Bioscience Investor Relations
innovations@darebioscience.com
Source: Daré Bioscience, Inc.
| Daré Bioscience, Inc. and Subsidiaries | |||||||
| Consolidated Statements of Operations and Comprehensive Loss | |||||||
| (Unaudited) | |||||||
| Three Months Ended September 30, | |||||||
| 2026 | 2025 | ||||||
| Revenue | |||||||
| Research and development services and other revenue | $ | 47,628 | $ | 2,262 | |||
| Total revenue | 47,628 | 2,262 | |||||
| Cost of revenues | 180,479 | - | |||||
| Operating expenses | |||||||
| Selling, general and administrative | $ | 2,640,388 | $ | 2,499,242 | |||
| Research and development | 318,906 | 1,175,168 | |||||
| Total operating expenses | 2,959,294 | 3,674,410 | |||||
| Loss from operations | (3,092,145 | ) | (3,672,148 | ) | |||
| Other (expense) income, net | (65,791 | ) | 109,382 | ||||
| Net loss | $ | (3,157,936 | ) | $ | (3,562,766 | ) | |
| Foreign currency translation adjustments | $ | 6,586 | $ | 6,860 | |||
| Comprehensive loss | $ | (3,151,350 | ) | $ | (3,555,906 | ) | |
| Loss per common share - basic and diluted | $ | (0.18 | ) | $ | (0.28 | ) | |
| Weighted average number of shares outstanding: | |||||||
| Basic and diluted | 17,421,580 | 12,755,112 | |||||
| Daré Bioscience, Inc. and Subsidiaries | |||||||
| Condensed Consolidated Balance Sheets Data | |||||||
| September 30, 2026 | December 31, 2025 | ||||||
| (unaudited) | |||||||
| Cash and cash equivalents | $ | 11,531,684 | $ | 24,711,356 | |||
| Working capital | $ | 3,210,505 | $ | 3,378,192 | |||
| Total assets | $ | 22,098,552 | $ | 32,474,563 | |||
| Total stockholders' equity | $ | 2,341,375 | $ | 2,842,634 | |||
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were Daré Bioscience's third-quarter 2026 financial results?
Daré reported revenue of approximately $48,000 and a net loss of approximately $3.2 million for the quarter ended September 30, 2026. Revenue was approximately $2,300 and net loss approximately $3.6 million in the prior-year quarter.
When will Daré Bioscience begin dispensing DARE to PLAY?
Daré expects prescription dispensing of DARE to PLAY Sildenafil Cream to begin in November 2026 in 28 states through the Section 503B compounding pathway. Prescriptions have been written across 48 states and Washington, D.C.; efforts continue to obtain dispensing licenses in the remaining states.
How does grant funding affect Daré Bioscience's reported research and development expenses?
Daré records grant and governmental funding as reductions to research and development expenses as related costs are incurred over the grant period. These offsets totaled approximately $4.7 million in the third quarter of 2026, compared with approximately $5.0 million in the third quarter of 2025.